According to sources, AI drug developer Insilico Medicine plans to list in Hong Kong and has appointed China International Capital Corporation and Morgan Stanley to advance the work. Insilico Medicine is expected to raise about 0.2 billion US dollars.

Insilico Medicine, established in 2014, mainly provides artificial intelligence software for pharmaceutical and biotechnology companies. It was reported at the end of 2021 that they applied to go public in the United States.

Insilico Medicine, after several rounds of financing, has investors including Wuxi Apptec, Hillhouse Capital, Temasek Holdings, Qiming Venture Partners, Sequoia Capital China, Fosun Pharma, SDIC Fund Management, Eli Lilly and Co Asia Fund, Innovation Works, Orbimed, Baidu Ventures, Source Code Capital, Prosperity7 Ventures, Bohai Huamei, B Capital Group, Qiming Venture Partners, Bold Capital Partners, Deerfield Management, Pavilion Capital, WS Investment, Formic Ventures, Mirae Asset Global Investments, Maixing Investments, Sage Partners, President International Development Corporation, F-Prime Capital, Juvenescence, Deep Knowledge Ventures, and more.